CC-401An ATP-competitive JNK inhibitor

CC-401 (CAS 395104-30-0)

CC-401 | CAS 395104-30-0 is rated 5.0 out of 5 by 1.
  • y_2019, m_9, d_17, h_8
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364748, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 83ms
  • REVIEWS, PRODUCT
Synonym: 3-[3-[2-(1-Piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole, CC401
Application: An ATP-competitive JNK inhibitor
CAS Number: 395104-30-0
Purity: ≥98%
Molecular Weight: 388.47
Molecular Formula: C22H24N6O
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

CC-401 is a second generation ATP-competitive anthrapyrazolone JNK (c-Jun N terminal kinase) inhibitor with potential antineoplastic activity.

Appearance :
Powder
Physical State :
Solid
Solubility :
Soluble in DMSO.
Storage :
Store at -20° C
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
10430360
SMILES :
C1CCN(CC1)CCOC2=CC=CC(=C2)C3=NNC4=C3C=C(C=C4)C5=NC=NN5

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

CC-401  Product Citations

See how others have used CC-401. Click on the entry to view the PubMed entry .

Citations 1 to 3 of 3 total

PMID: # 30190333  Insua-Rodríguez, J.|Pein, M.|Hongu, T.|Meier, J.|Descot, A.|Lowy, CM.|De Braekeleer, E.|Sinn, HP.|Spaich, S.|Sütterlin, M.|Schneeweiss, A.|Oskarsson, T.| et al. 2018. EMBO Mol Med. 10:

PMID: # 26134322  Evason, KJ. et al. 2015. PLoS Genet. 11: e1005305.

PMID: # 26058558  Zhang, H. et al. 2015. Journal of medical virology. 87: 2135-44.

Citations 1 to 3 of 3 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 93ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Vasilevskaya et al Vasilevskaya et al. (PubMed ID 26023085) found that the JNK inhibitor, CC-401, sensitized hypoxic colon cancer cells to DNA-damaging agents. -SCBT Publication Review
Date published: 2015-03-10
  • y_2019, m_9, d_17, h_8
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364748, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 46ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.